Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity

Biochemical Pharmacology

Volumn 79, Issue 3, 2010, Pages 307-320

  Wang, Chunmei ^a   Pimple, Surekha ^a   Buolamwini, John K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Benzopyranone derivatives; CoMFA; CoMSIA; Concentrative nucleoside transporters; Structure activity relationships

Indexed keywords

3',4' DIHYDROXYFLAVONE; 3',4' DIMETHOXYFLAVONE; 3,4' DIHYDROXYFLAVONE; 3,5 DIHYDROXYFLAVONE; 3,6 DIHYDROXYFLAVONE; 3,7 DIHYDROXYFLAVONE; 4',6 DIHYDROXYFLAVONE; 5,6 DIHYDROXYFLAVONE; 6 HYDROXY 7 METHOXYFLAVONE; 6,7 DIHYDROXYFLAVONE; 7,2' DIHYDROXYFLAVONE; 7,4' DIHYDROXYFLAVONE; 7,8 DIHYDROXYFLAVONE; 7,8 DIMETHOXYFLAVONE; ALPHA NAPHTHOFLAVONE; BENZOPYRONE DERIVATIVE; BETA NAPHTHOFLAVONE; CHALCONE DERIVATIVE; CHRYSIN; COUMARIN DERIVATIVE; FLAVONE DERIVATIVE; ISOFLAVONE DERIVATIVE; NUCLEOSIDE TRANSPORTER; NUCLEOSIDE TRANSPORTER 1; NUCLEOSIDE TRANSPORTER 2; NUCLEOSIDE TRANSPORTER 3; NUCLEOSIDE TRANSPORTER INHIBITOR; PHLORIZIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HYDROGEN BOND; HYDROPHOBICITY; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOPYRANS; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; PURINE NUCLEOSIDES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 70449687880     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.028     Document Type: Article

References (39)

1. Griffith D.A., and Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286 (1996) 153-181
2. King A.E., Ackley M.A., Cass C.E., Young J.D., and Baldwin S.A. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27 (2006) 416-425
3. Jennings L.L., Hao C., Cabrita M.A., Vickers M.F., Baldwin S.A., Young J.D., et al. Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 40 (2001) 722-731
4. Latini S., and Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79 (2001) 463-484
5. Damaraju V.L., Damaraju S., Young J.D., Baldwin S.A., Mackey J., Sawyer M.B., et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22 (2003) 7524-7536
6. Pastor-Anglada M., Cano-Soldado P., Molina-Arcas M., Lostao M.P., Larráyoz I., Martínez-Picado J., et al. Cell entry and export of nucleoside analogues. Virus Res 107 (2005) 151-164
7. Molina-Arcas M., Trigueros-Motos L., Casado F.J., and Pastor-Anglada M. Physiological and pharmacological roles of nucleoside transporter proteins. Nucleosides Nucleotides Nucleic Acids 27 (2008) 769-778
8. Baldwin S.A., Beal P.R., Yao S.Y.M., King A.E., Cass C.E., and Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch: Eur J Physiol 447 (2004) 735-743
9. Gray J.H., Owen R.P., and Giacomini K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch: Eur J Physiol 447 (2004) 728-734
10. Huang Q.Q., Yao S.Y., Ritzel M.W., Paterson A.R., Cass C.E., and Young J.D. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J Biol Chem 269 (1994) 17757-17760
11. Che M., Ortiz D.F., and Arias I.M. Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na(+)-nucleoside cotransporter. J Biol Chem 270 (1995) 13596-13599
12. Wang J., Su S.F., Dresser M.J., Schaner M.E., Washington C.B., and Giacomini K.M. Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am J Physiol 273 (1997) F1058-F1065
13. Ritzel M.W., Yao S.Y., Huang M.Y., Elliott J.F., Cass C.E., and Young J.D. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 272 (1997) C707-C714
14. +-nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 15 (1998) 203-211
15. +-nucleoside cotransporter (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleoside (system cib). J Biol Chem 276 (2001) 2914-2927
16. Yao S.Y., Ng A.M., Slugoski M.D., Smith K.M., Mulinta R., Karpinski E., et al. Conserved glutamate residues are critically involved in Na+/nucleoside cotransport by human concentrative nucleoside transporter 1 (hCNT1). J Biol Chem 282 (2007) 30607-30617
17. Damaraju V.L., Elwi A.N., Hunter C., Carpenter P., Santos C., Barron G.M., et al. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. Am J Physiol Renal Physiol 293 (2007) F200-F211
18. Pastor-Anglada M., Cano-Soldado P., Errasti-Murugarren E., and Casado F.J. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 38 (2008) 972-994
19. Pastor-Anglada M., Errasti-Murugarren E., Aymerich I., and Casado F.J. Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem 63 (2007) 97-110
20. Buolamwini J.K. Nucleoside transporter inhibitors: structure-activity relationships and potential therapeutic applications. Curr Med Chem 4 (1997) 35-66
21. Kwon O., Eck P., Chen S., Corpe C.P., Lee J.H., Kruhlak M., et al. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J 21 (2007) 366-377
22. Ward J.L., Sherali A., Mo Z.P., and Tse C.M. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 275 (2000) 8375-8381
23. Cramer III R.D., Patterson D.E., and Bunce J.D. comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110 (1988) 5959-5967
24. Klebe G., Abraham U., and Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37 (1994) 4130-4146
25. Toan S., To K.K., Leung G.P., Souza M.O., Ward J.L., and Tse C. Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells. Eur J physiol 447 (2003) 195-204
26. Gupte A., and Buolamwini J.K. Synthesis and biological evaluation of Phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett 19 (2009) 917-921
27. Smith K.M., Ng A.M., Yao S.Y., Labedz K.A., Knaus E.E., Wiebe L.I., et al. Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. J Physiol 558 (2004) 807-823
28. Zhang J., Smith K.M., Tackaberry T., Visser F., Robins M.J., Nielsen L.P., et al. Uridine binding and transportability determinants of human concentrative nucleoside transporters. Mol Pharmacol 68 (2005) 830-839
29. Lang T.T., Young J.D., and Cass C.E. Interactions of nucleoside analogs, caffeine, and nicotine with human-concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol Pharmacol 65 (2004) 925-933
30. Visser F., Zhang J., Raborn R.T., Baldwin S.A., Young J.D., and Cass C.E. Residue 33 of human equilibrative nucleoside transporter 2 is a functionally important component of both the dipyridamole and nucleoside-binding sites. Mol Pharmacol 67 (2005) 1291-1298
31. +/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J Biol Chem 280 (2005) 25436-25449
32. Chang C., Swaan P.W., Ngo L.Y., Lum P.Y., Patil S.D., and Unadkat J.D. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol 65 (2004) 558-570
33. Hu H., Endres C.J., Chang C., Umapathy N.S., Lee E.W., Fei Y.J., et al. Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol Pharmacol 69 (2006) 1542-1553
34. Nonaka Y, Tatani K, Hiratochi M, Kuramochi Y, Isaji M. Preparation of 5'-modified nucleoside derivatives as CNT-2 inhibitors. WO 2004101593; 2004.
35. Kikuchi N., Nonaka Y., Tatani K., Hiratochi M., Kuramochi Y., Isaji M., et al. Preparation of ribofuranoside compounds having benzimidazole moiety as CNT2 inhibitors. PCT Int Appl (2005) 141
36. Tatani, K.N.Y., Kikuchi, N. Preparation of purine nucleoside derivatives modified in 8-position as inhibitors of concentrative nucleoside transporter 2. WO 2006030803; 2006.
37. Mackey J.R., Yao S.Y., Smith K.M., Karpinski E., Baldwin S.A., Cass C.E., et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91 (1999) 1876-1881
38. Rius M., Stresemann C., Keller D., Brom M., Schirrmacher E., Keppler D., et al. Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther 8 (2009) 225-231
39. Errasti-Murugarren E., Pastor-Anglada M., and Casado F.J. Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J Physiol 582 (2007) 1249-1260